Akorn, Inc. Launches Tetanus Diphtheria Vaccine
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced the launch of Tetanus Diphtheria Vaccine to customers in the United States. These vaccine shipments effectively begin Akorn’s exclusive three year Tetanus Diphtheria distribution agreement with Massachusetts Biologic Laboratories.